Choice between delayed food and immediate oxycodone in rats.
The choice to seek immediate drug effects instead of more meaningful but delayed rewards is a defining feature of addiction.



To develop a rodent model of this behavior, we allowed rats to choose between immediate intravenous delivery of the prescription opioid oxycodone (50 μg/kg) and delayed delivery of palatable food pellets.



Rats preferred food at delays up to 30 s, but they chose oxycodone and food equally at 60-s delay and preferred oxycodone over food at 120-s delay. Comparison of food-drug choice, food-only, and drug-only conditions indicated that food availability decreased drug intake, but drug availability increased food intake. In the food-only condition, food was effective as a reinforcer even when delayed by 120 s. Pre-session feeding with chow slowed acquisition of food and drug self-administration, but did not affect choice. To establish procedures for testing potential anti-addiction medications, noncontingent pre-treatment with oxycodone or naltrexone (analogous to substitution and antagonist therapies, respectively) were tested on a baseline in which oxycodone was preferred over delayed food. Naltrexone pre-treatment decreased drug intake and increased food intake. Oxycodone pre-treatment decreased drug intake, but also produced extended periods with no food or drug responding.



These findings show that the contingencies that induce preference for drugs over more meaningful but less immediate rewards in humans can be modeled in rodents, and they suggest that the model could be useful for assessing the therapeutic potential of treatments and exploring the underlying behavioral and neural mechanisms involved in addiction.
Preclinical Pharmacology Section, Behavioral Neuroscience Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, US Department of Health and Human Services, 251 Bayview Blvd, Baltimore, MD, USA.
Maria E
ME
Secci
Preclinical Pharmacology Section, Behavioral Neuroscience Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, US Department of Health and Human Services, 251 Bayview Blvd, Baltimore, MD, USA.
Julie A
JA
Factor
Preclinical Pharmacology Section, Behavioral Neuroscience Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, US Department of Health and Human Services, 251 Bayview Blvd, Baltimore, MD, USA.
Charles W
CW
Schindler
Preclinical Pharmacology Section, Behavioral Neuroscience Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, US Department of Health and Human Services, 251 Bayview Blvd, Baltimore, MD, USA. lpanlili@intra.nida.nih.gov.
Leigh V
LV
Panlilio
D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000494:pharmacology; D000818:Animals; D016739:Behavior, Addictive / Q000523:psychology; D001522:Behavior, Animal / Q000187:drug effects*; D002755:Choice Behavior / Q000187:drug effects*; D065786:Delay Discounting; D004195:Disease Models, Animal; D004435:Eating / Q000187:drug effects; D005247:Feeding Behavior / Q000523:psychology*; D006801:Humans; D008297:Male; D009271:Naltrexone / Q000494:pharmacology; D010098:Oxycodone / Q000008:administration & dosage* / Q000494:pharmacology; D051381:Rats; D012201:Reward; D013997:Time Factors
D000701:Analgesics, Opioid; D009271:Naltrexone; D010098:Oxycodone
Addiction; Animal models; Behavioral economics; Concurrent choice; Delay discounting; Impulsivity
Psychopharmacology (Berl). 2005 Mar;178(2-3):193-201
15338104
Curr Drug Abuse Rev. 2012 Dec;5(4):257-72
23062106
Psychopharmacology (Berl). 2013 Sep;229(2):323-30
23636304
J Exp Anal Behav. 1981 May;35(3):335-51
7241034
J Exp Anal Behav. 2013 Jan;99(1):32-57
23344987
Addict Biol. 2009 Jan;14(1):22-31
18855805
Neuropharmacology. 2014 Jan;76 Pt B:518-27
23806805
Pharmacol Rev. 1975 Sep;27(3):357-65
817307
Q J Exp Psychol B. 1996 Nov;49(4):289-306
8962537
Adv Pharmacol Sci. 2012;2012:281768
23243420
Nicotine Tob Res. 2004 Oct;6(5):819-28
15700917
Eur J Pharmacol. 2008 Sep 11;592(1-3):109-15
18652823
Neuropharmacology. 2014 Jan;76 Pt B:510-7
23748095
Prog Neurobiol. 2013 Sep;108:44-79
23856628
Behav Neurosci. 2010 Aug;124(4):470-7
20695646
Neurosci Biobehav Rev. 2010 Nov;35(2):172-84
20417231
Neuropsychopharmacology. 2013 Jun;38(7):1209-20
23322185
Biol Psychiatry. 2015 Oct 1;78(7):463-73
25861699
J Pharmacol Exp Ther. 2006 May;317(2):711-23
16456085
Exp Clin Psychopharmacol. 2015 Jun;23(3):184-93
25938515
PLoS One. 2010 Jul 28;5(7):e11592
20676364
Psychopharmacology (Berl). 2008 Sep;200(1):1-26
18600315
Pharmacol Biochem Behav. 2005 Feb;80(2):309-26
15680184
PLoS One. 2007 Aug 01;2(8):e698
17668074
Psychopharmacology (Berl). 2015 Apr;232(7):1279-89
25327444
J Exp Anal Behav. 2013 Mar;99(2):211-33
23319458
Neuropsychopharmacology. 2012 Nov;37(12):2605-14
22871910
Annu Rev Public Health. 2015 Mar 18;36:559-74
25581144
Physiol Behav. 2007 Aug 15;91(5):459-72
17081571
Psychopharmacology (Berl). 2015 Apr;232(8):1451-60
25366874
Int J Obes (Lond). 2009 Jun;33 Suppl 2:S54-8
19528981
Neuropsychopharmacology. 2016 Jan;41(2):646-57
26129679
Psychopharmacology (Berl). 2011 Sep;217(2):177-87
21487658
Behav Processes. 2012 Mar;89(3):314-8
22209910
J Exp Anal Behav. 1963 Jul;6:317-22
13944949
Behav Processes. 1995 Jul;34(2):153-60
24897515
J Exp Psychol Gen. 1999 Mar;128(1):78-87
10100392
Psychopharmacology (Berl). 2012 Oct;223(4):477-87
22588252
Psychopharmacology (Berl). 2003 Apr;167(1):9-19
12644888
Psychopharmacology (Berl). 2006 May;186(1):99-106
16568283
Psychopharmacology (Berl). 2000 May;150(1):61-6
10867977
Addict Biol. 2015 May;20(3):433-44
24602027